News & events

Press releases

See all press releases

Conferences

November 29 - December 4, 2020 | Virtual Event

RSNA 2020

Median will be exhibiting at the RSNA 2020 Annual Meeting, which will take place from November 29 to December 4. Stop by our virtual booth to learn more about our  Imaging Phenomics platform iBiopsy®. Happy to see you there during the whole exhibition duration, from November 30 to December 3.

Visit conference website
See all conferences

In the press

iBiopsy® for Precision Medicine

Check out our paper published in the European Medical Journal on December 13, 2018 in order to educate the oncology specialists across Europe and the US as to the high-throughput artificial intelligence powered image-base phenotyping platform, iBiopsy® -> http://viewer.zmags.com/publication/647c38a3#/647c38a3/50

Abstract

A high-throughput artificial intelligence-powered image-based phenotyping platform, iBiopsy® (Median Technologies, Valbonne, France), which aims to improve precision medicine, is discussed in the presented review. The article introduces novel concepts, including high-throughput, fully automated imaging biomarker extraction; unsupervised predictive learning; large-scale content-based image-based similarity search; the use of large-scale clinical data registries; and cloud-based big data analytics to the problems of disease subtyping and treatment planning. Unlike electronic health record-based approaches, which lack the detailed radiological, pathological, genomic, and molecular data necessary for accurate prediction, iBiopsy® generates unique signatures as fingerprints of disease and tumor subtypes from target images. These signatures are then merged with any additional omics data and matched against a large-scale reference registry of deeply phenotyped patients. Initial applications targeted include hepatocellular carcinoma and other chronic liver diseases, such as nonalcoholic steatohepatitis. This new disruptive technology is expected to lead to the identification of appropriate therapies targeting specific molecular pathways involved in the detected phenotypes to bring personalised treatment to patients, taking into account individual biological variability, which is the principal aim of precision medicine.

See all in the press

Blog

See all blog entries

Webinars

DECEMBER 3rd, 2020

Regulatory Considerations on Imaging Endpoint Procedures in Oncology Trials: a Comparison of China NMPA and FDA Guidelines

In April 2020, The China National Medical Products Administration (NMPA) regulatory agency publicly solicited opinions on the draft guidelines on “Standard and Technical Guidelines for Imaging Endpoint Procedures for Clinical Trials of Anti-tumor Drugs”.

  • How the new regulations affect the endpoint selection of cancer drug approval?
  • What are the key differences compared with FDA guidelines?
  • How to select qualified imaging vendors for this activity to accelerate the drug approval in a compliant and efficient manner?

In this presentation, Dr. Yan Liu, Median’s CMO and a member of the expert panel who developed the NMPA guidelines, as well as Mr. Faisel Jobrani, Head of Median QA provide you with a clear vision based on concrete examples.

Presenters

Watch webinar video
See all webinars